MARKETWIRE.NET

Decode Your Next Market Move

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global Cell Surface Markers market. Market segmentation includes Product (Antibodies and PCR Arrays).

Find Out More About Regions, Brands, Dominant, Active & Niche Companies Covered in the Report

24 November 3:44 a.m., Silicon Valley, California - According to the new market research report, the global market for Cell Surface Markers is projected to grow at a CAGR of 8.9% to reach US$1.1 billion by 2027, driven by increasing use in research, disease diagnosis, drug discovery, personalized medicine and direct treatment for a specific medical condition. These markers allow researchers to determine cell expression of specific receptors to gain insights into biological response. Cell surface markers are commonly used to evaluate cell proliferation and abnormal cell population along with assessment and quantification of residual diseases. The increasing focus on timely diagnosis for disease prevention and reducing burden on healthcare system is driving the demand for cell surface markers. The market for cell surface markers is also driven by increasing adoption of sophisticated analytical technologies and in-vitro diagnostic tools as a result of ongoing efforts to reduce disease and to reduce healthcare burden.

The global market for cell surface markers is bolstered by rising cases of cancer and autoimmune diseases, creating the need for disease identification and automation solutions. In 2018, there were nearly 17 million new cases of cancer and around 9.5 million associated mortalities globally. The number of new cases and related deaths are projected to exceed 27.5 million and 16.3 million, respectively, by 2040, creating strong demand for cell surface markers for timely detection of cancer. The market is also benefitting from rising application of stem cell technology, advances in healthcare technology, and efforts to reduce disease diagnosis costs. Increasing geriatric population is expected to push healthcare spending and the need for effective, timely diagnostic techniques to aid treatment. These efforts are anticipated to present attractive opportunities for cell surface markers over the medium term. These markers are expected to experience robust demand across emerging markets like Asia-Pacific.

The cell surface markers market is anticipated to present lucrative opportunities for participants owing to continuing advancements in the field of surface markers. The emergence of new therapies to target liver cancer stem cells is expected to improve overall efficacy of traditional radiotherapy and chemotherapy procedures intended to treat liver cancer. One of the noteworthy developments in this direction is the identification of an ATP-competitive mTOR inhibitor, INK128, which holds potential to suppress CD44+, a liver cancer stem cell surface marker, along with sorafenib-insensitive hepatocellular carcinoma in-vivo and in-vitro. On the other hand, the complexity and lack of desirable expertise related to the use of flow cytometers are hindering the market growth. Low awareness across regions, such as Asia-Pacific and the Middle East, is inhibiting broader adoption of sophisticated flow cytometers. These instruments are also facing issues in terms of quantity of concurrent measurements, spectral overlap areas, data accuracy, complicated data processing, and automation of cluster identification.

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. All analysis and findings published in the report are based on validated engagements from a total executive pool size of 9602. Among this pool, 1344 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 288 unique participations, a total of 131 validated responses were received as part of this report's primary research outreach program.

Key Competitors Covered in the Report -
Merck KGaA
Thermo Fisher Scientific, Inc.
Bio-Rad Laboratories, Inc.
BD Biosciences
Danaher Corporation
R&D Systems, Inc.
F. Hoffmann-La Roche AG
Qiagen, Inc.
Abcam PLC
BioLegend, Inc.
Cell Signaling Technology, Inc.
GenScript Biotech Corporation

Segments Covered in the Report -
Product (Antibodies, PCR Arrays)
Cell Type (T Cell, B Cell, NK Cell, Monocyte Cell, Other Cell Types)
Application (Research, Clinical)
End-Use (Academic & Research Institutes, Hospitals & Clinical Laboratories, Other End-Uses)

Geographies Analyzed in the Report -
World
USA
Canada
Japan
China
Europe
France
Germany
Italy
UK
Spain
Russia
Rest of Europe
Asia-Pacific
Australia
India
South Korea
Rest of Asia-Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East
Iran
Israel
Saudi Arabia
UAE
Rest of Middle East
Africa.

View Executive Engagement Dashboards, COVID Impact Questionnaires & Get Complimentary Access to Methodology & Full-Text Secondary Sources

For enquiries e-mail us at sales@strategyR.com .

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world`s only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com